Last reviewed · How we verify
Placebo to match amlodipine
This is an inert placebo formulation designed to match the appearance and administration of amlodipine for use in blinded clinical trials.
This is an inert placebo formulation designed to match the appearance and administration of amlodipine for use in blinded clinical trials. Used for Use as control in clinical trials comparing amlodipine efficacy and safety.
At a glance
| Generic name | Placebo to match amlodipine |
|---|---|
| Sponsor | Organon and Co |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo-to-match products are inactive formulations engineered to be indistinguishable from the active drug in terms of appearance, taste, texture, and packaging. They are used in randomized controlled trials to maintain blinding and reduce bias. This specific placebo is formulated to match amlodipine, a calcium channel blocker, but contains no active pharmaceutical ingredient.
Approved indications
- Use as control in clinical trials comparing amlodipine efficacy and safety
Common side effects
Key clinical trials
- Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy (PHASE3)
- Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (PHASE2)
- Efficacy of Losartan + Amlodipine Compared to Amlodipine Alone in the Treatment of Uncontrolled High Blood Pressure (MK-0954F-399) (PHASE4)
- Evaluation of Celecoxib Effects on Amlodipine in Subjects With Existing Hypertension Requiring Antihypertensives (PHASE3)
- Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure (PHASE4)
- Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy (PHASE3)
- Essential Hypertension (PHASE2)
- An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to match amlodipine CI brief — competitive landscape report
- Placebo to match amlodipine updates RSS · CI watch RSS
- Organon and Co portfolio CI